Gilead Hits Cipla With Patent Suit Over HIV Drug Emtriva

Law360, New York (August 21, 2012, 2:22 PM EDT) -- Gilead Sciences Inc. lodged a suit against Cipla Ltd. in New York federal court Monday, claiming the generic drugmaker infringed two patents covering its drug Emtriva, a medication used to treat HIV patients.

Foster City, Calif.-based Gilead, along with Emory University, filed the suit after Cipla allegedly sought U.S. Food and Drug Administration approval to make and market emtricitabine capsules — the generic version of Emtriva — in violation of Gilead’s patent rights.

“On information and belief, the commercial manufacture, use, sale and/or importation of tablets...
To view the full article, register now.